Hanmi Pharmaceutical expects U.S. FDA approval for 2 new drugs
Condividi: 18 gennaio 2021 SEOUL, South Korea, Jan. 18, 2021 /PRNewswire/ — Hanmi Pharmaceutical Co., Ltd. plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields.
In particular, two new drugs developed by Hanmi Pharmaceutical Co., Ltd. are expected to be approved by the U.S. FDAleggi di più…